<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378075</url>
  </required_header>
  <id_info>
    <org_study_id>PTC743-MIT-001-EP</org_study_id>
    <secondary_id>2020-002100-39</secondary_id>
    <nct_id>NCT04378075</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy</brief_title>
  <acronym>MIT-E</acronym>
  <official_title>Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that&#xD;
      includes a 28-day run-in phase to establish baseline seizure frequency, followed by a&#xD;
      24-week, randomized, placebo-controlled phase. After completion of the randomized,&#xD;
      placebo-controlled phase, participants may enter a 48-week, long-term, extension phase during&#xD;
      which they will receive open-label treatment with vatiquinone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">July 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 18, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 24 in the Number of Observable Motor Seizures per 28 Days</measure>
    <time_frame>Day 0, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Disease-Related Hospital Days</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Occurrences or Recurrence of Status Epilepticus</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Disease-Related In-Patient Hospitalizations or Emergency Room Visits</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Disease-Related In-Patient Hospital Admissions or Emergency Room Visits</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 72 in Total Seizure Frequency (All Types) per 28 Days</measure>
    <time_frame>Day 0, Week 24, Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ≥25%, ≥50%, ≥75%, and 100% Reduction in Motor Seizures</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ≥25%, ≥50%, ≥75%, and 100% Reduction in Total Seizures (All Types)</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Require Rescue Seizure Medication</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life as Measured by the Care-Related Quality of Life of Informal Caregivers (CarerQoL-7D) Questionnaire</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Seizure Clusters</measure>
    <time_frame>Week 24 and up to Week 72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mitochondrial Diseases</condition>
  <condition>Drug Resistant Epilepsy</condition>
  <condition>Leigh Disease</condition>
  <condition>Leigh Syndrome</condition>
  <condition>Mitochondrial Encephalopathy (MELAS)</condition>
  <condition>Pontocerebellar Hypoplasia Type 6 (PCH6)</condition>
  <condition>Alpers Disease</condition>
  <condition>Alpers Syndrome</condition>
  <arm_group>
    <arm_group_label>Vatiquinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 milligrams/kilogram (mg/kg) if body weight &lt;13 kg, and 200 mg if body weight ≥13 kg, administered orally, 3 times per day (TID) or up to 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vatiquinone-matching placebo, administered orally, TID for up to 24 weeks followed by vatiquinone 15 mg/kg if body weight &lt;13 kg, and 200 mg if body weight ≥13 kg, administered orally, TID for up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vatiquinone</intervention_name>
    <description>Vatiquinone will be administered per the treatment arm description.</description>
    <arm_group_label>Vatiquinone</arm_group_label>
    <other_name>PTC743</other_name>
    <other_name>EPI-743</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vatiquinone-matching placebo will be administered per the treatment arm description</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vatiquinone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Participant or parent/legal guardian is able and willing to complete seizure diaries&#xD;
             for the duration of the study.&#xD;
&#xD;
          -  Genetic confirmation of inherited mitochondrial disease with associated epilepsy&#xD;
             phenotype (Alpers/polymerase subunit gamma [POLG], Leigh syndrome, mitochondrial&#xD;
             encephalopathy, lactic acidosis, and stroke-like episodes [MELAS], or other&#xD;
             genetically confirmed mitochondrial disease secondary to mitochondrial mutation).&#xD;
&#xD;
          -  Despite ongoing treatment with at least 2 antiepileptic drugs:&#xD;
&#xD;
               -  have ≥6 observed motor seizures occurring during the 28 days prior to the&#xD;
                  baseline visit (Day 0).&#xD;
&#xD;
               -  have ≥2 observed motor seizures in the first 14 days and ≥2 in the second 14 days&#xD;
                  of the Run-in period (Day -14).&#xD;
&#xD;
               -  do not have a consecutive 20-day seizure free period.&#xD;
&#xD;
               -  have at least 80% of seizure diary data.&#xD;
&#xD;
          -  Documented medical history of epilepsy associated with mitochondrial disease for at&#xD;
             least 6 months prior to screening.&#xD;
&#xD;
          -  Consent to abstain from non-approved therapies for 30 days prior to the baseline visit&#xD;
             (Day 0) and for the duration of the study.&#xD;
&#xD;
          -  Stable dose regimen of antiepileptic therapies 60 days prior to the baseline visit&#xD;
             (Day 0).&#xD;
&#xD;
          -  Stable regimen of dietary supplements 30 days prior and, if on a ketogenic diet,&#xD;
             stable ketogenic diet 90 days prior to the baseline visit (Day 0) and for duration of&#xD;
             the study.&#xD;
&#xD;
          -  Electroencephalogram (EEG) at screening or historical EEG for diagnostic confirmation&#xD;
             of seizures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to vatiquinone or sesame oil.&#xD;
&#xD;
          -  Aspartate transaminase (AST) or alanine transaminase (ALT) ≥2 × upper level of normal&#xD;
             (ULN) at time of screening.&#xD;
&#xD;
          -  International normalized ratio (INR) ≥1.5 × ULN at time of screening.&#xD;
&#xD;
          -  Serum creatinine ≥1.5 × ULN at time of screening.&#xD;
&#xD;
          -  Participation in another interventional clinical trial 60 days prior to randomization&#xD;
             or for the duration of this clinical trial&#xD;
&#xD;
          -  Previously received vatiquinone.&#xD;
&#xD;
          -  Concomitant treatment with drug(s) that have not received regulatory agency approval&#xD;
             for the treatment of mitochondrial diseases.&#xD;
&#xD;
          -  Concomitant treatment with idebenone.&#xD;
&#xD;
          -  Ongoing treatment with cytochrome P450 (CYP) inhibitors such as itraconazole or CYP&#xD;
             inducers such as rifampin. Treatment with these agents must be completed at least 4&#xD;
             weeks prior to enrollment.During the study, participants should not use grapefruit&#xD;
             juice or St John's wort extract.&#xD;
&#xD;
          -  Pregnant or lactating participants or those sexually active participants who are&#xD;
             unwilling to comply with proper birth control methods. Females of childbearing&#xD;
             potential must have a negative pregnancy test at screening and during the baseline&#xD;
             visit (Day 0).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinay Penematsa, MD</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-562-4620</phone>
    <email>medinfo@ptcbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Haas, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Enns, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center - Department Of Neurology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea L. Gropman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Genetics Clinic (Main MGH Hospital)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amel Karaa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irina A. Anselm, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vikas Bhambhani, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruce Cohen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fernando Scaglia, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mary Kay Koenig, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Russel Saneto, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Malattie Muscolari e Neurodegenerative, Dipartimento di Scienze Neurologiche e Psichiatriche, Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrico Silvio Bertini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marcello Bellusci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shamima Rahman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert McFarland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POLG</keyword>
  <keyword>polymerase gamma</keyword>
  <keyword>ALPERS</keyword>
  <keyword>MELAS</keyword>
  <keyword>PCH6</keyword>
  <keyword>Pontocerebellar hypoplasia type 6</keyword>
  <keyword>MERRF</keyword>
  <keyword>intractable epilepsy</keyword>
  <keyword>Mitochondrial disease</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Motor seizures</keyword>
  <keyword>Non-Motor seizures</keyword>
  <keyword>Seizure</keyword>
  <keyword>Refractory epilepsy</keyword>
  <keyword>Status epilepticus</keyword>
  <keyword>Ferroptosis</keyword>
  <keyword>Neurodegeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
    <mesh_term>Leigh Disease</mesh_term>
    <mesh_term>Diffuse Cerebral Sclerosis of Schilder</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

